Holen Sie sich die Stockscreener-App
3.93
2.08%
0.08
Vorhandelsmarkt:
3.93
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
This Analyst Slashed CAPR Stock’s Target By 86% – But, Retail Bulls Say Setup Offers An Attractive Risk-Reward - Yahoo Finance
Capricor Therapeutics Faces Severe Stock Decline Amid FDA Concer - GuruFocus
CAPR Investor Alert: Capricor Therapeutics Investors Encouraged t - The National Law Review
Capricor Therapeutics: Downgrading To Sell As FDA Doubts Mount (NASDAQ:CAPR) - Seeking Alpha
Capricor Stock Tanks On FDA AdCom NotesWhat Investors Should Know (NASDAQ:CAPR) - Seeking Alpha
Replimune joins Capricor in post-briefing doc drop (REPL:NASDAQ) - Seeking Alpha
Alliance Global Partners Reiterates "Neutral" Rating for Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
B. Riley Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $10 From $63 - marketscreener.com
Roth Capital Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $7 From $38 - Moomoo
FDA panel raises doubts over Capricor’s deramiocel data ahead of DMD review - The Pharma Letter
CAPR|Capricor Therapeutics Inc|Price:7.000|Chg%:-12.700 - TradingKey
BREAKING: Capricor Therapeutics Investigated for Securities Fraud by Block & Leviton; Investors Should Contact the Firm to Learn More - Supply Chain Digital
Biotech Firms Face Critical FDA Review Events - Intellectia AI
Capricor’s Deramiocel Briefing Is a Masterclass in How Not to Define an Endpoint - The Clinical Trial Vanguard
Capricor Therapeutics Inc (CAPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Securities Investigation on Behalf of Capricor Investors - ACCESS Newswire
B.Riley downgrades Capricor stock on FDA briefing concerns By Investing.com - Investing.com UK
Capricor addresses FDA briefing materials ahead of advisory meeting - Investing.com India
CAPR Stock Eyes Worst Month In 9 Years On FDA Doubts — ‘Pharma Bro’ Shkreli Piles On, But Retail Turns More Bullish Than Ever - Stocktwits
Why Capricor Therapeutics (CAPR) Is Down 64.1% After FDA Flags Deramiocel Trial Concerns And Headquarters Bet - simplywall.st
Rosen Law Firm Encourages Capricor Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CAPR - Business Wire
Capricor Therapeutics (CAPR) Faces FDA Advisory Vote Amid Steep Stock Decline - GuruFocus
Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug - STAT
CAPR Plunged About 64% After FDA Briefing Docs Hit. AdCom Is Wednesday. - Money Morning
FDA briefing casts doubt on Capricor’s deramiocel ahead of DMD AdCom - AllSci
Capricor Therapeutics (CAPR) Downgraded as FDA Briefing Raises A - GuruFocus
Capricor Therapeutics (CAPR) Shares Plunge Amid FDA Data Concerns, GF Score™ at 28 - GuruFocus
FDA staff report throws cold water on Capricor's DMD cell therapy bid - FirstWord Pharma
CAPR Investor Alert: Kehoe Law Firm, P.C. Investigates Capricor T - The National Law Review
UPDATE: FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy - BioSpace
Capricor Therapeutics (NASDAQ:CAPR) Stock Rating Lowered by Roth Capital - MarketBeat
CAPR Stock On Track For Worst Day Ever — Analysts Divided On Deramiocel’s Approval Probability After FDA Documents Paint ‘Ugly Picture’ - Stocktwits
FDA staff flags data concerns about Capricor's therapy; shares plunge | Business Information & News | FE - Westlaw Today
Capricor Therapeutics stock falls after FDA briefing ahead of AdCom By Investing.com - Investing.com Australia
Capricor Therapeutics stock falls after FDA briefing ahead of AdCom - Investing.com
Investigation launched into Capricor Therapeuti... - Pluang
Market movers: Nvidia, Advanced Micro Devices, Capricor Therapeutics, SpaceX… - Proactive financial news
Capricor stock plunges 70% after FDA questions trial data for heart therapy. - Pluang
Capricor Therapeutics (CAPR) Prepares for FDA Advisory Committee Review on Deramiocel - GuruFocus
Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel - GlobeNewswire
Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel - GlobeNewswire Inc.
CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC - GlobeNewswire
Capricor Therapeutics (CAPR) Shares Plunge 67% After FDA Briefin - GuruFocus
H.C. Wainwright reiterates Capricor stock Buy rating at $60 target - Investing.com
Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Benzinga
Capricor Therapeutics (CAPR) Stock Plummets 63% Amid FDA Advisor - GuruFocus
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Capricor Therapeutics faces securities fraud pr... - Pluang
B.Riley downgrades Capricor stock on FDA briefing concerns - Investing.com
BREAKING: Capricor Therapeutics Investigated for Securities - GlobeNewswire
Capricor Therapeutics’ 67.7% collapse and the warning signs that preceded it - Investing.com
$Capricor Therapeutics (CAPR.US)$ waaa hit my first 🎯 - Moomoo
Capricor Therapeutics (NASDAQ:CAPR) Receives Neutral Rating from B. Riley Financial - MarketBeat
Adcom ‘cage match’ in store for Capricor? - BioWorld News
FDA scientists question Capricor data; Legend CEO steps down - BioPharma Dive
Capricor Therapeutics (NASDAQ:CAPR) shares tumble 67% after FDA raises concerns over Deramiocel data - TechStock²
Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document - Stocktwits
Oppenheimer reiterates Capricor stock rating ahead of FDA panel By Investing.com - Investing.com South Africa
Capricor addresses FDA briefing materials ahead of advisory meeting By Investing.com - Investing.com South Africa
FDA staff flags data concerns about Capricor's therapy; shares plunge - Reuters
Capricor Therapeutics stock tumbles after FDA briefing documents - Investing.com
Capricor updates ahead of FDA advisory meeting on Duchenne muscular dystrophy therapy Deramiocel. - Pluang
Capricor Provides Update on Deramiocel for DMD Ahead of FDA Meeting - Intellectia AI
Capricor Therapeutics Provides Update Ahead of FDA Advisory Committee Meeting on Deramiocel BLA for Duchenne Muscular Dystrophy - Quiver Quantitative
0.39%
1.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):